HURA

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestonesTAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company's pipeline, ongoing clinical trials, and general corporate expenses.  The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC.Under the terms of the

424B5 - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic developmentTAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Amanda Garofalo, MSHS, as Senior Vice President (SVP) of Clinical Operations.Mrs. Garofalo, who brings over 20 years of clinical and development experience, will work closely with Craig Tendler, M.D., and oversee day-to-day clinical operations."We warmly welcome Amanda to the TuHURA team," said James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosc

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter and full year ended December 31, 2025, and provided a corporate update."2025 was a strong year of executing upon our goals, and we continue to move all our programs forward this year. As we progress our clinical development pipeline, we have strategically strengthened our clinical and drug development expertise with Craig Tendler, M.D., providing the strategic and operational services consistent with those o

10-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March 23, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L. Tendler will provide strat

TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the "Listing Rule"). Nasdaq confirmed that for the last 11 consecutive business days, from February 10, 2026, through February 25, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or grea

TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer, will participate in the following upcoming investor conferences:Citizens Life Science ConferenceDate: Tuesday, March 10, 2026Time: 4:00 pm ETLinks: To register and view presentation, click HERE. A live and archived webcast of the presentation will also be available through the investors page of TuHURA's corporate website at https://ir.tuhurabio.com/news-events/events.Leerink Global Healthcare Con

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

SCHEDULE 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AMLTAMPA, Fla., Feb. 17, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration's (FDA) Division of Hematologic Malignancies 1 (DHM1) for the study of TBS-2025, a novel VISTA inhibiting antibody, for the treatment of mutNPM1 relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) in combination with a menin inhibitor.The Company plans on initiating

TAMPA, Fla., Feb. 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Date: February 26, 2026Time: 3:20 pm ETLinks: To register and view presentation, click HERE A live and archived webcast of the presentation will be available through the investors page of TuHURA's corporate website at https://ir.tuhurabio.com/news-events/events. About TuHURA Biosciences, Inc. Tu

TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. The ODD designation was based on data from the Company's previously completed Phase 1 study of IFx-2.0, results of which were published in the journal Molecular Therapeutics and entitled: "First-in-Human Stage II/IV Melanoma Clinical Trial of Immune Priming

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)